- Home
- Automated
- List of product information
- MENQUADFI SOLUTION FOR INJECTION [SIN16454P]
MENQUADFI SOLUTION FOR INJECTION [SIN16454P]
Active ingredients: MENQUADFI SOLUTION FOR INJECTION
Last updated 26 October 2025
On this page
Product Info
MENQUADFI SOLUTION FOR INJECTION
[SIN16454P]
Product information
Active Ingredient and Strength | MENINGOCOCCAL POLYSACCHARIDE, SEROGROUP A (MONOVALENT CONJUGATE) - 10 MCG/0.5 ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | SANOFI PASTEUR, INC. - UNITED STATES |
Registration Number | SIN16454P |
Licence Holder | SANOFI-AVENTIS SINGAPORE PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07AH08 |
Therapeutic indications
MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.
The use of this vaccine should be in accordance with available official recommendations.
Posology and method of administration
Posology
Primary vaccination:
Individuals 12 months of age and older: One single dose (0.5 mL).
Booster vaccination:
A single 0.5 mL dose of MenQuadfi may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups (see section Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Long-term antibody persistence data following vaccination with MenQuadfi are available up to 7 years after vaccination (see sections Special warnings and precautions for use and Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
There are no data available to indicate the need for or timing of a booster dose of MenQuadfi (see section Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Other paediatric population
The safety and immunogenicity of MenQuadfi in individuals under 12 months of age have not yet been established.
Method of administration
For intramuscular injection only, preferably in the deltoid region or anterolateral thigh depending on the recipient's age and muscle mass.
For instructions on handling of the vaccine before administration, see section Special precautions for disposal and other handling – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section List of excipients or after previous administration of the vaccine or a vaccine containing the same components – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.